Physician profile
Ronald E Calhoun
NPI 1942210745
$3,532.90
in general payments reported to CMS, 2019-2025
31 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $706 · 2021: $579 · 2022: $402 · 2023: $580 · 2024: $600 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,581.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $971.75 | 2020-2025 | Relistor, Xifaxan, Trulance |
| Novo Nordisk INC | $594.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $311.01 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $277.45 | 2023-2024 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $232.88 | 2020-2025 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $148.96 | 2021-2024 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $88.91 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.31 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.62 | 2023-2025 | Caplyta |
| Amgen INC. | $66.57 | 2020-2025 | Otezla, Repatha |
| Corcept Therapeutics | $65.80 | 2024-2025 | Korlym |
| Indivior INC. | $64.42 | 2020-2025 | Sublocade |
| Astellas Pharma US INC | $59.47 | 2023-2025 | Veozah |
| Braeburn INC. | $58.94 | 2024-2025 | Brixadi |
| Inspire Medical Systems, INC. | $49.04 | 2025 | Inspire |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $42.37 | 2025 | Voquezna |
| Amarin Pharma, INC. | $41.80 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $38.83 | 2025 | Rexulti |
| Antares Pharma, INC. | $32.51 | 2019-2020 | |
| Pfizer INC. | $30.84 | 2020 | |
| Idorsia Pharmaceuticals US INC | $25.82 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.24 | 2024 | |
| Sanofi-Aventis U.S. LLC | $19.07 | 2019 | |
| Scilex Pharmaceuticals INC. | $17.62 | 2022 | |
| Scynexis, INC. | $16.12 | 2022 | |
| Esperion Therapeutics, INC. | $15.62 | 2020 | |
| Axsome Therapeutics, INC. | $15.07 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $13.67 | 2020 | |
| Abbott Laboratories | $13.29 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Calhoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.